Sphera Funds Management’s Puma Biotechnology PBYI Stock Holding History

Sphera Funds Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-60,000	Closed	-$4.08M	–	118
2018 Q1	$4.08M	Buy	60,000 +25,000	+71%	+$1.87M	0.62%	50
2017 Q4	$3.46M	Buy	+35,000	New	+$3.92M	0.41%	59
2015 Q2	–	Sell	-13,796	Closed	-$3.26M	–	150
2015 Q1	$3.26M	Sell	13,796 -6,500	-32%	-$1.39M	0.34%	72
2014 Q4	$3.84M	Sell	20,296 -10,000	-33%	-$2.22M	0.65%	48
2014 Q3	$7.23M	Buy	30,296 +5,296	+21%	+$1.09M	0.89%	29
2014 Q2	$1.65M	Buy	+25,000	New	+$1.78M	0.41%	59

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sphera Funds Management's PBYI Position: Q2 2018 in Review

Sphera Funds Management sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 60,000 shares — an estimated $4.08M sold.

Sphera Funds Management first reported a position in PBYI in Q2 2014 and held it in 6 quarters. The position peaked at $7.23M in Q3 2014. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

Sphera Funds Management reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
Sphera Funds Management sold 60,000 Puma Biotechnology shares in Q2 2018, an estimated $4.08M.
Sphera Funds Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 6 quarters.
Sphera Funds Management's Puma Biotechnology position peaked at $7.23M in Q3 2014.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.